SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2007 / Cilt: 7 - Sayı: 3

Yeni antidepresanların kardiyovasküler yan etkileri

Cardiovascular side effects of newer antidepressants

Antony FERNANDEZ
Suji E. BANG
Komandur SRİVATHSAN
W. Victor R. VİEWEG
Pages
305–309
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Newer antidepressants should be considered as first-line agents for the treatment of depression in patients with and without cardiovascular disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We review the cardiovascular effects of newer antidepressants.
📊
Key Findings & Data:Although further studies are warranted, the safety of the selective serotonin reuptake inhibitors and the serotonin norepinephrine reuptake inhibitors on patients with comorbid cardiac conditions is impressive.
💡
Conclusion & Impact:Newer antidepressants should be considered as first-line agents for the treatment of depression in patients with and without cardiovascular disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We review the cardiovascular effects of newer antidepressants. Although further studies are warranted, the safety of the selective serotonin reuptake inhibitors and the serotonin norepinephrine reuptake inhibitors on patients with comorbid cardiac conditions is impressive. Newer antidepressants should be considered as first-line agents for the treatment of depression in patients with and without cardiovascular disease.

Özet

Bu derlemede yeni antidepresanların kardiyovasküler yan etkilerini gözden geçirdik. İleride yeni çalışmaların yapılması gerekli olsa da, komorbid kardiyak problemleri olan hastalarda selektif serotonin gerialım inhibitörlerinin ve serotonin norepinefrin gerialım inhibitörlerinin güvenlik profilleri etkileyicidir. Yeni antidepresanlar, kardiyovasküler hastalıkları olan veya olmayan hastalarda depresyon tedavisinde birincil ajanlar olarak düşünülmelidirler.

🔖

Cite This Article

FERNANDEZ, A., BANG, S. E., SRİVATHSAN, K., VİEWEG, W. V. R. (2022). Yeni antidepresanların kardiyovasküler yan etkileri. Anadolu Kardiyoloji Dergisi, Cilt: 7 - Sayı: 3, 305–309. https://ajindex.com/articles/437115

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Vieweg WVR, Julius DA, Fernandez A, Wulsin LR, Mohanty PK, Beatty-Brooks M, et al. Treatment of depression in patients with coronary heart disease. Am J Med 2006; 119: 567-73
  2. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819-25
  3. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis following myocardial infarction. Circulation 1995; 91: 999-1005
  4. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-80
  5. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94: 3123-9
  6. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 221-7
  7. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TL. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415-26
  8. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112-20
  9. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
  10. Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28: 520-6
  11. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 1: 930-57
  12. Glassman AH. Citalopram toxicity. Lancet 1997; 350: 818
  13. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 87-8
  14. Kincaid RL, McMullin MM, Crookham SB, Rieders F. Report of a fluoxetine fatality. J Anal Toxicol 1990; 14: 327-9
  15. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet 1996; 348: 339-40
  16. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993; 54 (Suppl): 3-15
  17. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23: 435-40
  18. Glassman AH. Cardiovascular effects of antidepressa